TFXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
TELEFLEX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$129.68−0.75 (-0.58%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- 1.05%
TELEFLEX INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $1.28B | $1.16B | $1.18B | $1.93B | $1.66B | $1.47B | $1.49B | $1.35B | – | – | 64.2% | +10.6% |
| EMEA | $472.41M | $340.26M | $316.97M | $558.37M | $606.81M | $584.86M | $588.04M | $603.81M | – | – | 23.7% | +38.8% |
| Asia | $241.11M | $202.35M | $214.76M | $306.32M | $297.77M | $267.02M | $294.33M | $286.90M | – | – | 12.1% | +19.2% |
| OEM | – | – | $326.01M | $272.62M | $245.68M | $220.25M | $220.72M | $205.98M | $182.97M | $160.99M | – | – |
| Asia | – | – | – | – | – | – | $294.33M | $286.90M | $269.21M | $249.42M | – | – |
| Anesthesia North America | – | – | – | – | – | – | – | – | – | $198.77M | – | – |
| Surgical North America | – | – | – | – | – | – | – | $166.27M | $175.22M | $172.22M | – | – |
| EMEA | – | – | – | – | – | – | $588.04M | $603.81M | $552.72M | $510.93M | – | – |
| All other | – | – | – | – | – | – | – | $389.25M | $233.98M | $198.06M | – | – |
| Americas | – | – | – | – | – | – | $1.49B | $1.35B | $1.14B | $295.21M | – | – |
| Anesthesia North America | – | – | – | – | – | – | – | $205.06M | $197.98M | $198.77M | – | – |
| Interventional North America | – | – | – | – | – | – | – | $261.65M | $220.61M | $82.43M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vascular | $917.73M | $903.51M | $841.11M | $683.61M | $700.24M | $657.70M | $600.87M | $575.33M | $540.23M | – | 46.1% | +1.6% |
| Interventional | $647.79M | $397.34M | $407.25M | $445.02M | $427.50M | $382.44M | $427.56M | $395.42M | $324.68M | – | 32.5% | +63.0% |
| Surgical | $418.16M | $404.87M | $388.33M | $392.92M | $377.76M | $317.20M | $370.07M | $358.71M | $356.16M | – | 21.0% | +3.3% |
| Other | $9.04M | -$6.18M | $75.75M | $285.15M | $336.59M | $367.26M | $347.27M | $366.85M | $358.71M | – | 0.5% | -246.3% |
| OEM | – | $344.51M | $326.01M | $272.62M | $245.68M | $220.25M | $220.72M | $205.98M | $182.97M | – | – | – |
| Anesthesia | – | $395.29M | $389.96M | $388.89M | $380.14M | $302.29M | $338.41M | $349.37M | $344.60M | – | – | – |
| Interventional urology | – | $331.09M | $319.79M | $322.83M | $341.66M | $290.02M | $290.45M | $196.74M | $38.96M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.18B | $1.08B | $1.11B | $1.79B | $1.77B | $1.57B | $1.61B | $1.45B | $1.25B | $1.02B | 59.3% | +9.5% |
| Europe | $484.73M | $347.90M | $330.07M | $622.34M | $665.00M | $646.58M | $652.07M | $671.26M | $591.37M | $208.84M | 24.3% | +39.3% |
| Asia Pacific | $218.03M | $179.57M | $187.95M | $270.75M | $263.02M | $230.27M | $241.28M | $234.09M | $220.11M | – | 10.9% | +21.4% |
| All other | $108.13M | $92.74M | $87.53M | $111.48M | $112.05M | $93.17M | $95.77M | $93.60M | $80.00M | $73.08M | 5.4% | +16.6% |
| Spain, Italy, Portugal, and Greece | – | – | – | – | – | – | – | $142.70M | $129.40M | $125.30M | – | – |
| Europe | – | – | – | – | – | – | – | $671.26M | $591.37M | $567.32M | – | – |
From the segment and revenue-disaggregation notes of Teleflex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.